SEARCH

SEARCH BY CITATION

References

  • 1
    Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164 76.
  • 2
    Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229 36.
  • 3
    Arroyo V, Gines P, Jimenez V, Rodes J. Renal dysfunction in cirrhosis. In: McIntyre N, Benemou JP, Rhodes J, eds. Oxford Textbook of Clinical Hepatology. 1999: 733–61.
  • 4
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151 7.
  • 5
    Moore K. The hepatorenal syndrome. Clin Sci 1997; 92: 433 43.
  • 6
    McCormick PA, Chin JKT, Nair DR, et al. Nitric oxide synthase inhibitors in the hepatorenal syndrome [1]. European J Gastroenterol Hepatol 1993; 5: 59 60.
  • 7
    Schrier RW, Niederberger M, Weigert A, Gines P. Peripheral arterial vasodilation: Determinant of functional spectrum of cirrhosis. Seminars Liver Dis 1994; 14: 14 22.
  • 8
    Gines P, Fernandez-Esparrach G, Arroyo V, Rodes J. Pathogenesis of ascites in cirrhosis. Seminars Liver Dis 1997; 17: 175 89.
  • 9
    Epstein M. Renal prostaglandins and the control of renal function in liver disease. Am J Med 1986; 80: 46 55.
  • 10
    Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Seminars Nephrol 1997; 17: 530 48.
  • 11
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774 8.
  • 12
    Zipser RD, Radvan GH, Kronborg I, Duke R, Little TE. Urinary Tromboxane B2 and prostaglandin E2 in the hepatorenal syndrome. Gastroenterology 1983; 84: 697 703.
  • 13
    Vallance P & Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776 8.
  • 14
    Guarnier C, Soriano G, Tomas, et al. Increased serum nitrite levels in patient with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139 43.
  • 15
    Goilis J, Patch D, Burroughs A. The role of bacterial infections in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139 42.DOI: 10.1016/s0140-6736(98)06020-6
  • 16
    Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998; 28: 416 22.
  • 17
    Jalan R, Hayes PC, Redhead DN. Shunt insufficiency after TIPSS. Cardiovasc Intervent Radiol 1998; 21: 187 8.
  • 18
    Gines P & Navasa M. Management of ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis in cirrhosis. Curr Opin Gastroenterol 1995; 11: 233 7.
  • 19
    Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis 1994; 14: 71 81.
  • 20
    Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome: New perspectives in pathogenesis and treatment. Arch Intern Med 1993; 153: 1957 67.
  • 21
    Gentilini P & Laffi G. Pathophysiology and treatment of ascites and the hepatorenal syndrome. Baillieres Clin Gastroenterol 1992; 6: 581 607.
  • 22
    Cohn J, Tristani F, Khatri I. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man. Circulation 1968; 28: 151 7.
  • 23
    Kew MC, Varma RR, Sampson DJ, Sherlock S. The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 1972; 13: 293 6.
  • 24
    Gentilini P. Hepatorenal syndrome and ascites—an introduction. Liver 1999; 19(Suppl.): 5 14.
  • 25
    Lenz K, Druml W, Kleinberger G. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut 1985; 26: 1385 6.
  • 26
    Lenz K, Hortnagl H, Druml W, Grimmm G, et al. Beneficial effects of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989; 101: 1060 7.
  • 27
    Lenz K, Hortnagl H, Druml W, Reihter H, Schimd R, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991; 101: 1060 7.
  • 28
    Salo J, Gines A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996; 25: 916 23.
  • 29
    Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35 41.
  • 30
    Hadengue A, Gadano, Giostra E, Moreau R, Valla D, Lebrec D. Terlipressin in the treatment of hepatorenal syndrome: A double blind crossover study. Hepatology 1995; 22 (A236): 165165.
  • 31
    Bonnard Ph, Bernard B, Halim Ch, Mathurin P. Effect of terlipressin in hepatorenal syndrome in cirrhotic patients: results of a pilot study. Gastroenterology 1998; 114: 12141214.
  • 32
    Ganne-Carri N, Hadengue A, Mathurin P, et al. Hepatorenal syndrome: Long-term treatment with terlipressin as a bridge to liver transplantation. Digestive Dis Sci 1996; 41: 1054 6.
  • 33
    Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565 70.
  • 34
    Angeli P, Volpin R, Piovan D, et al.Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937 43.
  • 35
    Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [2]. J Hepatol 1999; 30: 174174.
  • 36
    Vincenti F & Goldberg LI. Combined use of dopamine and prostaglandine A1 in patients with acute renal failure and hepatorenal syndrome. Prostaglandins 1978; 15: 463 72.
  • 37
    Bennett WM, Keefe E, Melnyk K, Mahler D, Rosch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964 71.
  • 38
    Ames R, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and cirrhosis with ascites. J Clin Invest 1965; 44: 1171 86.
  • 39
    Fevery J, Cutsem E, Van Nevens F, Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990; 11: 153 8.
  • 40
    Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993; 17: 220 6.
  • 41
    Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347: 1842 3(Letter).